Testosterone Therapy

AbbVie Profits Rise 4.3% as Testosterone Lawsuits Mount

abbvie profits on the risePharmaceutical giant AbbVie, Inc. has reported a 4.3 percent increase in its first-quarter profits, according to Nasdaq. The Chicago-based company cited heightened sales of anti-inflammatory medications, and detailed its plans to keep its top-selling drug Humira afloat.

Despite the rise in profits, AbbVie still faces financial trouble in the form of testosterone lawsuits. The company’s popular “low-T” product, AndroGel, is one of a handful or prescription testosterone treatments that have ...

continue reading...

Health Experts Accuse “Low-T” Drug Manufacturers of “Disease Mongering”

medical experts fire back at low t campaignA recent Forbes article explores the prevalence of “Low-T” drug ads by companies like AbbVie and Eli Lilly & Co., and how two men’s health experts think the advertisements should be banned.

Testosterone therapy products have been associated with an increased risk of serious cardiovascular health effects. A study published in November 2013 linked testosterone therapy to increased rates of heart attack, stroke, and death. Another study ...

continue reading...

Testosterone MDL Cases Now Total over 1,500

testosterone therapy MDL cases now over 1500According to the website of the U.S. District Court for the Northern District of Illinois, the multidistrict testosterone therapy litigation MDL 2545 now includes 1,530 testosterone lawsuits—nearly 200 more than it did just one month ago. The multidistrict testosterone litigation was established in June 2014, and initially consisted of eight separate testosterone lawsuits. Testosterone lawsuits claim that testosterone therapy products from companies like AbbVie and Eli Lilly caused ...

continue reading...

Testosterone Drug Approval Slowed After Patient Develops Allergic Reaction

testosterone therapy drug causes allergic reactionAntares Pharma Incorporated saw dramatic falls in its stock price after hitting a roadblock in clinical trials of its prescription testosterone product. A patient developed an allergic reaction to the drug during the trial, causing the U.S. Food and Drug Administration (FDA) to request additional safety information. A Reuters’ article discusses the setback for the testosterone therapy manufacturer.

Concerns over the safety of prescription testosterone products have been on the ...

continue reading...

Androgel Manufacturer Drops Plan to Purchase Shire

First Word Pharma reports that Androgel maker AbbVie has abandoned its plan to buy out pharmaceutical maker Shire. AbbVie says the bid for Shire was withdrawn in light of recent U.S. tax law changes. As a result of the failed deal, AbbVie will have to pay $1.6 billion to Shire and will be unable to make another offer to purchase the company for at least a year.

The Androgel maker was recently in the news over allegations ...

continue reading...

Thumbs Down to Testosterone Therapy for Women

A recent story posted by MedlinePlus notes new guidelines from the Endocrine Society. The guidelines say no testosterone therapy for women as the benefits are not clear and the risks of testosterone therapy are unknown in women.

Although there is some research indicating that testosterone therapy may be helpful to sexual function in menopausal women, a statement by the Endocrine Society says there are too many unanswered questions about the risks of testosterone therapy in this ...

continue reading...
Page 4 of 8 «...23456...»